EvAluation de Satisfaction Infirmière (Nurse Satisfaction Evaluation). Observational Study of the Preparation and Intramuscular Administration of the Previous and New Long-Acting Release Octreotide LAR Formulation (EASI) Abstract #2802

Introduction: A new formulation of octreotide LAR (OCT LAR) with a new diluent has been developed to facilitate the preparation and administration.
Aim(s): To compare nurse’s satisfaction about preparation and administration through a visual analogic scale from 0 (unsatisfied) to 10 (very satisfied) of both previous and new formulations of OCT LAR.
Materials and methods: French oncologists, endocrinologists and gastroenterologists were contacted to include patients in the study. All patients treated with OCT LAR for acromegaly (ACRO), or endocrine digestive tumor (NET) were eligible. Patients were included at 2 different timelines: group 1 “previous formulation (PF)” and group 2 “new formulation (NF)”.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Alexandre Santos

To read results and conclusion, please login ...

Further abstracts you may be interested in

#215 Nurse Evaluation of Long-acting Somatostatin Analogue Injection Devices: A Quantitative Study
Introduction: The two major long-acting somatostatin analogues (SSA) available on the European market for the treatment of neuroendocrine tumors and acromegaly are Somatuline Autogel (SA) and Sandostatin LAR (LAR).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Hannah Kurth
#334 Everolimus + Octreotide LAR v. Placebo + Octreotide LAR in Patients With Advanced NET: Results of a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Trial (RADIANT-2)
Introduction: Everolimus, an oral inhibitor of mTOR, demonstrated promising antitumor activity in patients with NET as a single agent and in combination with octreotide LAR in two phase 2 studies.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Marianne Pavel
#493 Pasireotide and Octreotide LAR Was an Effective Combination in a Patient with Small Intestinal NET with Hypokalemia and a High Level of VIP
Introduction: Small Intestinal neuroendocrine tumors (NET) are argentaffin-positive tumors that progress slowly.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Gordana Kozlovacki
#3023 The Major Role of Neuroendocrine Tumor (NET)-Specialist Nurse in Improving NET Patients Disease-related QoL - Preliminary Data
Introduction: There is increasing evidence regarding the key role of dedicated specialist nurses in the treatment of cancer patients. Nurse coordinators serves as an available, accessible and knowledgeable resource for both patient and patient's family, more than the general registered nurses. They know better how to control symptoms and work as team players with multiple care providers.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: MPH Ilanit Emily Tal
#154 Long-term disease stabilization in a patient with advanced pancreatic neuroendocrine tumor treated with combined everolimus and octreotide LAR after prior failure of cytotoxic therapy
Introduction: Targeting of multiple pathways has become an important strategy for improved tumor control in metastatic neuroendocrine tumors (NETs). Among these targets is the mammalian target of rapamycin (mTOR), a central regulator of cell growth, proliferation, and apoptosis, which is blocked by everolimus, an oral inhibitor of mTOR that has shown efficacy in patients with metastatic pancreatic NETs. Recent evidence has suggested that suppression of insulin-like growth factor-1 receptor (IGF-1R) secretion with octreotide therapy, along with concurrent inhibition of mTOR by everolimus, may improve tumor control synergistically by preventing feedback activation of the PI3K/Akt/mTOR pathway.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Alexandre Teulé Vega